KR950703982A - ANTACID COMPOSITON AND METHOD OF PRODUCTION - Google Patents

ANTACID COMPOSITON AND METHOD OF PRODUCTION

Info

Publication number
KR950703982A
KR950703982A KR1019950702371A KR19950702371A KR950703982A KR 950703982 A KR950703982 A KR 950703982A KR 1019950702371 A KR1019950702371 A KR 1019950702371A KR 19950702371 A KR19950702371 A KR 19950702371A KR 950703982 A KR950703982 A KR 950703982A
Authority
KR
South Korea
Prior art keywords
antacid composition
antacid
mammal
particle size
composition
Prior art date
Application number
KR1019950702371A
Other languages
Korean (ko)
Inventor
게리 지 리버시지
그레고리 엘 멕킨타이어
Original Assignee
알프레드 피.로렌조
이스트만 코닥 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알프레드 피.로렌조, 이스트만 코닥 캄파니 filed Critical 알프레드 피.로렌조
Publication of KR950703982A publication Critical patent/KR950703982A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명은 평균 입자 크기가 약 3μ미만인 알루미늄계 중화제를 필수적으로 포함하는 입자를 함유하는 제산제 조성물 및 상기 조성물을 제조하는 방법에 관한 것이다. 이러한 조성물은 더 큰 입자를 갖는 조성물에 비해 현저하게 향상된 중화 속도를 가지며, 포유 동물의 위산 관련 통증을 치료하는데 유용하다.The present invention relates to an antacid composition comprising particles essentially comprising an aluminum-based neutralizing agent having an average particle size of less than about 3 microns and a method of making the composition. Such compositions have significantly improved neutralization rates compared to compositions with larger particles and are useful for treating gastric acid related pain in mammals.

Description

제산제 조성물 및 제조방법(ANTACID COMPOSITON AND METHOD OF PRODUCTION)ANTACID COMPOSITON AND METHOD OF PRODUCTION

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

도면은 종래의 기술과 비교하여, 본 발명의 조성물을 위한 가상 위액의 중화속도가 증가하는 것을 나타낸 것이다.The figures show an increase in the rate of neutralization of the virtual gastric juice for the compositions of the present invention as compared to the prior art.

Claims (13)

필수적으로 알루미늄계 중화제로 구성되고 약 3μ미만인 평균 입자 크기를 갖는 입자를 포함하는 제산제 조성물.An antacid composition comprising particles essentially consisting of an aluminum-based neutralizer and having an average particle size of less than about 3 microns. 제1항에 있어서, 상기 중화제가 표면상에 흡착된 표면 변헝제를 갖는 제산제 조성물.The antacid composition of claim 1, wherein the neutralizer has a surface modifier adsorbed on the surface. 제1항에 있어서, 상기 중화제가 수산화알루미늄인 제산제 조성물.The antacid composition of claim 1, wherein said neutralizing agent is aluminum hydroxide. 제1항에 있어서, 마그네슘계 화합물 입자를 또한 포함하는 제산제 조성물.The antacid composition of claim 1, further comprising magnesium-based compound particles. 제4항에 있어서, 상기 마그네슘계 화합물이 수산화마그네슘인 제산제 조성물.The antacid composition according to claim 4, wherein the magnesium compound is magnesium hydroxide. 제2항에 있어서, 상기 표면 변형제가 시멘티콘인 제산제 조성물.The antacid composition according to claim 2, wherein the surface modifier is cementite. 제2항에 있어서, 상기 조성물이 5내지 80중량%의 상기 입자를 함유하는 제산제 조성물.The antacid composition according to claim 2, wherein the composition contains 5 to 80% by weight of the particles. 필수적으로 수산화마그네슘 및 수산화알루미늄으로 이루어지고 약 3μ미만의 평균 입자 크기를 갖는 입자를 포함하는 제산제 조성물.An antacid composition comprising particles essentially consisting of magnesium hydroxide and aluminum hydroxide and having an average particle size of less than about 3 microns. 제8항에 있어서, 상기 입자 크기가 약 1μ미만인 제산제 조성물.9. The antacid composition of claim 8, wherein said particle size is less than about 1 micron. (1)알루미늄계 중화제를 액체 분산 매질에 분산시키는 단계, 및 (2)분쇄 매질의 존재하에서 습식 분쇄하여 상기 중화제의 평균 입자 크기를 약 3μ미만으로 감소시키는 단계를 포함하는, 제1항의 제산제 조성물의 제조방법.The antacid composition of claim 1, comprising the steps of: (1) dispersing an aluminum-based neutralizer in a liquid dispersion medium, and (2) wet grinding in the presence of a grinding medium to reduce the average particle size of the neutralizer to less than about 3 microns. Manufacturing method. 효과량의 제1항의 제산제 조성물을 포유 동물에 투여함을 포함하는, 포유 동물의 치료 방법.A method of treating a mammal comprising administering to the mammal an effective amount of the antacid composition of claim 1. 효과량의 제6항의 제산제 조성물을 포유 동물에 투여함을 포함하는, 포유 동물의 치료 방법.A method of treating a mammal comprising administering to the mammal an effective amount of the antacid composition of claim 6. 효과량의 제8항의 제산제 조성물을 포유 동물에 투여함을 포함하는, 포유 동물의 치료 방법.A method of treating a mammal comprising administering to the mammal an effective amount of the antacid composition of claim 8. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019950702371A 1992-12-11 1993-12-03 ANTACID COMPOSITON AND METHOD OF PRODUCTION KR950703982A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98929692A 1992-12-11 1992-12-11
US07/989296 1992-12-11
PCT/US1993/011720 WO1994013304A2 (en) 1992-12-11 1993-12-03 Antacid composition and method of production

Publications (1)

Publication Number Publication Date
KR950703982A true KR950703982A (en) 1995-11-17

Family

ID=25534976

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950702371A KR950703982A (en) 1992-12-11 1993-12-03 ANTACID COMPOSITON AND METHOD OF PRODUCTION

Country Status (10)

Country Link
EP (1) EP0673253A1 (en)
JP (1) JPH08504442A (en)
KR (1) KR950703982A (en)
AU (1) AU6390894A (en)
CA (1) CA2150383A1 (en)
CZ (1) CZ148695A3 (en)
FI (1) FI952859A (en)
NO (1) NO952261L (en)
SK (1) SK76595A3 (en)
WO (1) WO1994013304A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3618348B2 (en) * 1993-08-24 2005-02-09 カッパ ファーマシューティカルズ リミテッド Reduced absorption of fatty acids
JP4303315B2 (en) 1994-05-09 2009-07-29 オックスフォード バイオメディカ（ユーケー）リミテッド Non-crossing retroviral vector
US5874112A (en) * 1997-03-31 1999-02-23 Mcneil Ppc-Inc. Translucent antacid suspension
AU2002951438A0 (en) * 2002-09-17 2002-10-03 Nauveau Technology Investments Ltd Methods and compositions for treatment of excess stomach acid in mammals
RU2013148719A (en) * 2013-10-31 2015-05-10 Геннадий Гильфанович Галимов COMPOSITION BASED ON MAGNESIUM CHLORIDE HYDROXOALUMINATE, CONTAINING MAGNESIUM HYDROXIDE, AS A THERAPEUTIC DRUG
WO2016104367A1 (en) * 2014-12-22 2016-06-30 株式会社Ｌｔｔバイオファーマ Functional dyspepsia therapeutic drug

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3843778A (en) * 1970-04-28 1974-10-22 Rorer Inc William H Antacids
US4271142A (en) * 1979-06-18 1981-06-02 Life Savers, Inc. Portable liquid antacids
FR2512344A1 (en) * 1981-09-08 1983-03-11 Af Aplicaciones Far Lab Stable antacid suspension of aluminium and/or magnesium hydroxide(s) - prepd. by mixing powdered prod. with water, fragmenting and dispersing to give particle size of 5-10 microns

Also Published As

Publication number Publication date
WO1994013304A2 (en) 1994-06-23
EP0673253A1 (en) 1995-09-27
FI952859A0 (en) 1995-06-09
WO1994013304A3 (en) 1994-09-01
FI952859A (en) 1995-06-09
NO952261D0 (en) 1995-06-08
CA2150383A1 (en) 1994-06-23
NO952261L (en) 1995-06-08
CZ148695A3 (en) 1995-12-13
SK76595A3 (en) 1997-01-08
JPH08504442A (en) 1996-05-14
AU6390894A (en) 1994-07-04

Similar Documents

Publication Publication Date Title
ES8501804A1 (en) Method for manufacturing aluminium- and boron-based composite alloys and application thereof.
AU4747293A (en) Use of tyloxapol as a nanoparticle stabilizer and dispersant
ES2182059T3 (en) PRECIPITATED SILICES PRESENTING IMPROVED CHARACTERISTICS OF EFFECTIVENESS IN DENTRIFICOS AND METHODS OF PREPARATION.
KR840005841A (en) Phosphor
CA2010239A1 (en) Curable filled polysiloxane compositions
KR970069878A (en) Silylated Silica
FR2398494A1 (en) PRODUCTS TO SPRAY ON THE HAIR
KR950703982A (en) ANTACID COMPOSITON AND METHOD OF PRODUCTION
DE1519151A1 (en) Process for the production of waterproof, stabilized silicone greases
CA2111758A1 (en) Personal Care Compositions
MX9600667A (en) Useful composition for emulsion(s) mixture and polyol polymer dispersion(s)-based paints and coating(s) prepared with this composition.
KR20210047188A (en) A composition for prevention of scattering a dust and a method for preparing the composition
MXPA05008790A (en) Compositions comprising a polysaccharide component and one or more coating layers.
EP0446754B1 (en) Glyceroxyfunctional silanes and siloxanes
JPS5964565A (en) Inorganic board
JP2002363018A (en) Antibacterial gel composition
RU95113584A (en) ANTACIDE COMPOSITIONS, METHOD OF OBTAINING ANTACID COMPOSITION, METHODS OF TREATING MAMMALS
KR890700022A (en) Pharmaceutical Vehicles to Reduce Skin Penetration Flow
US5208360A (en) Glyceroxyfunctional silanes and siloxanes
MX9600668A (en) Useful composition for emulsion(s) mixture and polyol polymer dispersion(s)-based coatings and coating(s) prepared with this composition.
CN1788861A (en) Slow erosion and sealed protection method for irony cultural relics
JP3671319B2 (en) Powder massage fee
KR960006926A (en) Complex Antacid Composition
JPS57187347A (en) Anti-fogging agent composition
JPH0131930B2 (en)

Legal Events

Date Code Title Description
N231 Notification of change of applicant
SUBM Surrender of laid-open application requested